✨ Free AI Report
Biohaven Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biohaven Ltd.
Company Research

Biohaven Ltd.: Business Overview, Financials & Competitive Analysis

Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Following Pfize...

Analyst-debate audio for Biohaven Ltd.

AskCyborg analysts argue the bull and bear cases for Biohaven Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with differentiated degrader platform and promising early data, but execution risk remains high in...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Biohaven Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Biohaven Ltd. Overview

Pro stress-test →

Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Following Pfizer's acquisition of the original Biohaven, the company spun off Biohaven Ltd., which retained the non-CGRP development stage pipeline including Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms.

Strategic Profile

Pro stress-test →

Biohaven is a leader in targeted extracellular protein degradation with its MoDE and TRAP degraders, utilizing ground-breaking science exclusively licensed from Yale. The company announced a restructuring to target a ~60% reduction in annual direct R&D spend while accelerating pivotal trials for degraders and opakalim in 2026.

Competitive Landscape

Pro stress-test →

Competitors include Neurogene, CuraSen, Quince Therapeutics, ACADIA Pharmaceuticals, and Biogen in the biopharmaceutical space. Biohaven differentiates through its proprietary MoDE and TRAP degrader platforms, with exclusive Yale licensing providing technological moat in extracellular protein degradation.

Industry Context

Biohaven Ltd. operates in Biopharmaceutical Development.

Key facts

Founded: 2022 · Headquarters: New Haven, Connecticut · Market cap: $1.58B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Biohaven Ltd..

  • Company raised $500.9M in total capital through Q4 2025 and early 2026, with cash and equivalents of $322M as of December 31, 2025, supplemented by $178.9M raised via share offerings in 2026.
  • In January 2026, Biohaven entered an MoU with King Abdullah University of Science and Technology to collaborate on next-generation degrader development leveraging AI and supercomputing capabilities.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Q4 2025 earnings reported with clinical data showing strong reductions in IgG and seizure activity across key degrader programs
  • January 2026MoU signed with KAUST for AI-enhanced degrader development and next-generation platform advancement
  • +1 moreTrack every material event for Biohaven Ltd. as it happens. Explore monitoring →
Get alerted when Biohaven Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Neurological & Psychiatric TherapiesNeuroscience-focused development stage biotech→Gene Therapy ProgramsCNS-focused gene therapy developer→Immunology & Oncology TherapeuticsClinical-stage immunology specialist→

Compare Biohaven Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biohaven Ltd. operates in Biopharmaceutical Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Development research →
NEW · MCP server

Ask your AI assistant about Biohaven Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biohaven Ltd. and its top competitor on Cyborg Score”
“What did Biohaven Ltd. do this quarter?”
“Is Biohaven Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Biohaven Ltd. do?+
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Following Pfize...
What is Biohaven Ltd.'s Cyborg Score?+
Biohaven Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biohaven Ltd.'s main competitors?+
Named competitors include Neurological & Psychiatric Therapies, Gene Therapy Programs, Immunology & Oncology Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Biohaven Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biohaven Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biohaven Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical Development research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Protagonist Therapeutics Inc.6Fortress Biotech, Inc.5NRx Pharmaceuticals, Inc.